

PATIENT INFORMATION:

Fax completed form, insurance information, and clinical documentation to 855.889.2946

Patient Name: _____ DOB: _____ Phone: _____

 Patient Status: New to Therapy Continuing Therapy **Next Treatment Date:** _____

MEDICAL INFORMATION

Patient Weight: _____ lbs. (required) Allergies: _____

THERAPY ORDER

Diagnosis	Medication Orders	Refills
<input type="checkbox"/> Crohn's Disease <input type="checkbox"/> Ulcerative Colitis <input type="checkbox"/> Other: _____ ICD-10 Code: _____	<input type="checkbox"/> Cimzia 400mg subQ at weeks 0, 2, 4 and then every 4 weeks <input type="checkbox"/> Cimzia _____ mg subQ every _____ weeks <input type="checkbox"/> Infliximab or infliximab biosimilar as required by patient's insurance <input type="checkbox"/> Do not substitute. Infuse the following infliximab product: _____ <i>For Paragon use only. Brand: _____</i> Dose: _____ mg/kg Frequency: <input type="checkbox"/> Every _____ weeks OR <input type="checkbox"/> 0, 2, 6 then every 8 weeks <input type="checkbox"/> Skyrizi initial infusion: <input type="checkbox"/> 600mg or <input type="checkbox"/> 1200mg IV at week 0, 4, and 8 weeks <input type="checkbox"/> Skyrizi maintenance*: <input type="checkbox"/> 180mg or <input type="checkbox"/> 360mg subQ at week 12, and every 8 weeks thereafter <input type="checkbox"/> Stelara initial infusion: <input type="checkbox"/> 260mg <input type="checkbox"/> 390mg <input type="checkbox"/> 520mg IV x 1 dose <input type="checkbox"/> Stelara maintenance*: <input type="checkbox"/> 90mg SQ 8 weeks after initial infusion and then every 8 weeks thereafter <input type="checkbox"/> Entyvio 300mg IV at 0, 2, 6 weeks and then Q8 weeks <input type="checkbox"/> Entyvio 300mg IV every 8 weeks <input type="checkbox"/> Entyvio 300mg IV at 0 and 2 weeks (IV to subQ dosing) <input type="checkbox"/> Omvo (initial infusion): <input type="checkbox"/> 300mg or <input type="checkbox"/> 900mg IV at 0, 4, and 8 weeks <input type="checkbox"/> Omvo (maintenance)*: <input type="checkbox"/> 200mg or <input type="checkbox"/> 300mg subQ at week 12, then every 4 weeks <input type="checkbox"/> Tremfya (initial infusion): 200mg IV at 0, 4, and 8 weeks <input type="checkbox"/> Tremfya (maintenance)*: <input type="checkbox"/> 100mg subQ at week 16, then every 8 weeks thereafter OR <input type="checkbox"/> 200mg subQ at week 12, then every 4 weeks thereafter *SubQ maintenance doses are filled by Paragon Specialty Pharmacy as applicable	<input type="checkbox"/> _____ <input type="checkbox"/> x1 year

ICD-10 Code: _____
 Iron Deficiency Anemia
 Iron Deficiency Anemia w/CKD
 Other: _____
 ** If the patient has Aetna, Cigna, Humana, or UHC, the patient must try and fail Venofer first or have a letter of medical necessity**

 Venofer 200mg IV - Administer 5 doses over a 14 day period
 Venofer 200mg IV weekly x 5 weeks
 Injectafer 15mg/kg IV (<50kg) - Give 2 doses at least 7 days apart
 Injectafer 750mg IV (≥50kg) - Give 2 doses at least 7 days apart
 Monoferric 1000mg IV x1 dose (≥50kg)
 Monoferric 20mg/kg IV x1 dose (<50kg)

Premedication orders: Tylenol 1000mg 500mg PO, please choose one antihistamine:
 Diphenhydramine 25mg PO Loratadine 10mg PO Cetirizine 10mg PO Cetirizine 10mg IVP
Additional premedications: Solu-Medrol _____ mg IVP Solu-Cortef _____ mg IVP Other _____
Lab orders: _____ **Frequency:** Every infusion Other: _____
 Yearly TB QFT Baseline HepBcAB total Required labs to be drawn by: Paragon Healthcare Referring Provider
 Home biologic IV Ana-kit (adult): Dispense EpiPen 0.3mg IM (2-pack) or compounded syringe, diphenhydramine 50mg IV and PO, NS 1000mL
 Home biologic injection Ana-kit (adult): EpiPen 0.3mg IM (2-pack)

PROVIDER INFORMATION

 By signing this form and utilizing our services, you are authorizing *Paragon Healthcare, Inc.* and its employees to serve as your prior authorization and specialty pharmacy designated agent in dealing with medical and prescription insurance companies, and to select the preferred site of care for the patient.

Provider Name: _____ Signature: _____ Date: _____

Provider NPI: _____ Phone: _____ Fax: _____ Contact Person: _____

 Opt out of Paragon selecting site of care (if checked, please list site of care): _____

PREFERRED LOCATION

City: _____ State: _____

View our locations here:



PATIENT INFORMATION:

Patient Name: _____ DOB: _____

REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL

- Include signed and completed order (MD/prescriber to complete page 1)
- Include patient demographic information and insurance information
- Include patient's medication list
- Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits, or contraindications to conventional therapy
 - For biologic orders, has the patient had a documented contraindication/intolerance or failed trial of a conventional therapy (i.e., 6MP, azathioprine)? Yes No
If yes, which drug(s)? _____
 - For biologic orders, does the patient have a contraindication/intolerance or failed trial to any other biologic (i.e., Humira, Stelara, Cimzia)? Yes No
If yes, which drug(s)? _____
- Include labs and/or test results to support diagnosis
- If applicable* - Last known biological therapy: _____ and last date received: _____. If patient is switching biologic therapies, please perform a wash-out period of _____ weeks prior to starting ordered biologic therapy.
- Other medical necessity: _____

REQUIRED PRE-SCREENING (BASED ON DRUG THERAPY)

- TB screening test completed within 12 months - attach results**
Required for: Cimzia, Infliximab, Stelara, Entyvio, Skyrizi, Omvoh, Tremfya
 Positive **Negative**
- Hepatitis B screening test completed (Hepatitis B surface antigen) - attach results**
Required for: Cimzia, Infliximab
 Positive **Negative**
- Liver function tests & bilirubin** Required for: Skyrizi, Omvoh
- Labs indicating iron deficiency** Required for: Venofer, Injectafer, Monoferric

*If TB or Hepatitis B results are positive - please provide documentation of treatment or medical clearance, and a negative CXR (TB+)

Paragon Healthcare will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

Please fax all information to (855) 889-2946 or call (877) 365-5566 for assistance